Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients
| Autor: | Clark B. Sherer, Theodore Lenox, Gary P. Wormser, Miguel Nunez, Omar Kawwaff, Christine Forszpaniak, Militza Suarez, Frederick P. Duncanson, Howard L. Quentzel, Katherine Freeman, Natalie C. Klein, Africa Pitta-alvarez |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Sexually transmitted disease medicine.medical_specialty medicine.medical_treatment Immunology urologic and male genital diseases Drug Administration Schedule law.invention Randomized controlled trial law Internal medicine Trimethoprim Sulfamethoxazole Drug Combination medicine Humans Immunology and Allergy Prospective Studies Prospective cohort study Pentamidine Acquired Immunodeficiency Syndrome Chemotherapy business.industry Pneumonia Pneumocystis bacterial infections and mycoses medicine.disease Trimethoprim female genital diseases and pregnancy complications Surgery Clinical trial Pneumonia Treatment Outcome Infectious Diseases Injections Intravenous Female business medicine.drug |
| Zdroj: | AIDS. 6:301-306 |
| ISSN: | 0269-9370 |
| Popis: | Objective To compare the clinical efficacy and safety of trimethoprim-sulfamethoxazole (TMP-SMX) with pentamidine in the therapy of Pneumocystis carinii pneumonia (PCP) in patients with AIDS. Patients, participants TMP-SMX (TMP, 20 mg/kg/day plus SMX, 100 mg/kg/day) was compared with pentamidine (4 mg/kg/day), both administered intravenously for 21 days in a prospective randomized treatment trial of 163 patients diagnosed with PCP between November 1984 and May 1988. Results Ninety-two evaluable patients received TMP-SMX as initial therapy; 68 received pentamidine. Failure to complete therapy was common. Of those receiving TMP-SMX, 39 (42%) required change in therapy because of failure to respond, and an additional 31 (34%) because of drug toxicity. This compared with 27 (40%; P = 0.733) and 17 (25%; P = 0.235), respectively, in the pentamidine-treated group. The overall survival rates were similar in the two groups, 62 out of 92 (67%) initially administered TMP-SMX versus 50 out of 68 (74%) initially administered pentamidine (P = 0.402). The survival rates for patients requiring a change in therapy because of failure to respond was 46% (18 out of 39) for the TMP-SMX group compared with 56% (15 out of 27) for the pentamidine group. When a change in therapy was made because of toxicity, survival rates were 97% (30 out of 31) for those receiving TMP-SMX versus 94% (16 out of 17) for those receiving pentamidine. Conclusion TMP-SMX and pentamidine are of equivalent efficacy as initial therapies for PCP in patients with AIDS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|